Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 134,685,328
  • Shares Outstanding, K 725,910
  • Annual Sales, $ 22,991 M
  • Annual Income, $ 7,722 M
  • 36-Month Beta 1.36
  • Price/Sales 6.04
  • Price/Cash Flow 12.64
  • Price/Book 4.17

Price Performance

See More
Period Period Low Period High Performance
1-Month
173.76 +8.20%
on 12/29/17
189.30 -0.68%
on 01/17/18
+10.97 (+6.20%)
since 12/15/17
3-Month
168.15 +11.81%
on 11/20/17
189.30 -0.68%
on 01/17/18
+1.82 (+0.98%)
since 10/17/17
52-Week
150.38 +25.02%
on 01/24/17
191.10 -1.62%
on 09/14/17
+33.21 (+21.45%)
since 01/17/17

Most Recent Stories

More News
FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head...

AMGN : 188.01 (+1.33%)
Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology

Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that...

AMGN : 188.01 (+1.33%)
Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News

Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.

CELG : 102.02 (-2.67%)
CNCE : 19.94 (+3.64%)
VRTX : 156.99 (+0.82%)
INCY : 90.31 (-1.46%)
GILD : 81.74 (+1.86%)
AMGN : 188.01 (+1.33%)
JUNO : 69.25 (+51.86%)
Will Amgen (AMGN) Continue to Tread Growth Path This Year?

Amgen (AMGN) stock outperformed the industry in 2017. We will have to wait and see if it can keep the momentum alive in 2018.

AGN : 176.72 (-1.09%)
RHHBY : 30.4500 (-0.75%)
AMGN : 188.01 (+1.33%)
PFE : 37.18 (+1.58%)
Novartis (NVS) Announces Acceptance of Humira BLA by the FDA

Novartis (NVS) Biologics License Application (BLA) for the proposed biosimilar of blockbuster drug Humira was accepted by the FDA under the 351 (k) pathway.

NVS : 86.88 (+0.17%)
EXEL : 27.49 (-7.28%)
ABBV : 104.36 (+1.82%)
AMGN : 188.01 (+1.33%)
4 ETFs Set to Surge in Q4 Earnings

Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank would lead to profits for investors.

CELG : 102.02 (-2.67%)
DHI : 52.10 (+2.50%)
ILMN : 242.05 (+0.26%)
CLR : 57.18 (+0.44%)
BBH : 128.83 (+0.18%)
AMGN : 188.01 (+1.33%)
TOL : 52.07 (+2.44%)
PMR : 38.86 (-0.51%)
LOW : 101.68 (+0.70%)
ITB : 45.85 (+1.96%)
BMRN : 89.64 (-0.66%)
INCY : 90.31 (-1.46%)
HD : 199.82 (+1.79%)
PXE : 24.10 (+1.26%)
EOG : 113.53 (+0.12%)
Global Immunology Market 2018-2022 with AbbVie, Amgen, F. Hoffmann-La Roche & Johnson & Johnson Dominating - Research and Markets

The "Global Immunology Market 2018-2022" report has been added to ResearchAndMarkets.com's offering.

JNJ : 146.98 (+0.08%)
AMGN : 188.01 (+1.33%)
4 ETFs Set to Surge in Q4 Earnings

Betting on ETFs with the winning combination of stocks that have a positive Earnings ESP and a favorable Zacks Rank would lead to profits for investors.

CELG : 102.02 (-2.67%)
DHI : 52.10 (+2.50%)
ILMN : 242.05 (+0.26%)
CLR : 57.18 (+0.44%)
BBH : 128.83 (+0.18%)
AMGN : 188.01 (+1.33%)
TOL : 52.07 (+2.44%)
PMR : 38.86 (-0.51%)
LOW : 101.68 (+0.70%)
ITB : 45.85 (+1.96%)
BMRN : 89.64 (-0.66%)
INCY : 90.31 (-1.46%)
HD : 199.82 (+1.79%)
PXE : 24.10 (+1.26%)
EOG : 113.53 (+0.12%)
The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

CELG : 102.02 (-2.67%)
VRTX : 156.99 (+0.82%)
EXEL : 27.49 (-7.28%)
AMGN : 188.01 (+1.33%)
ALXN : 122.12 (-1.90%)
Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?

Merck's (MRK) Keytruda rapidly grows as its key top-line driver. The Keytruda development program shows significant advancement in 2017.

MRK : 62.03 (-0.06%)
LLY : 86.21 (+1.08%)
AMGN : 188.01 (+1.33%)
PFE : 37.18 (+1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 191.14
1st Resistance Point 189.57
Last Price 188.01
1st Support Level 186.17
2nd Support Level 184.34

See More

52-Week High 191.10
Last Price 188.01
Fibonacci 61.8% 175.54
Fibonacci 50% 170.74
Fibonacci 38.2% 165.94
52-Week Low 150.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.